MK-3222
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $1.2M | 1,089 | 5 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.2M | 1,074 | 99.2% |
| Consulting Fee | $9,725 | 15 | 0.8% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A 64-Week, Phase 3, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety,Tolerability of Subcutaneous SCH 900222,MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis Protocol No. MK-3222-010 | Merck Sharp & Dohme Corporation | $620,782 | 1 |
| A 52-Week, Phase 3, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety,Tolerability of Subcutaneous SCH 900222,MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis Protocol NO. MK-3222-011 | Merck Sharp & Dohme Corporation | $595,640 | 0 |
Top Doctors Receiving Payments for MK-3222
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Alpharetta, GA | $1.2M | 1,064 |
| , M.D | Dermatology | High Point, NC | $19,295 | 10 |
| , M.D | Internal Medicine | Richmond, VA | $4,375 | 6 |
| , MD | Cardiovascular Disease | St Louis, MO | $2,900 | 4 |
| , M.D./PH.D | Neurology | San Diego, CA | $1,350 | 2 |
| , M.D | Cardiovascular Disease | Rochester, MN | $1,100 | 3 |
Manufacturing Companies
Product Information
- Type Biological
- Total Payments $1.2M
- Total Doctors 5
- Transactions 1,089
About MK-3222
MK-3222 is a biological associated with $1.2M in payments to 5 healthcare providers, recorded across 1,089 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2017. In 2017, $1.2M was paid across 1,089 transactions to 5 doctors.
The most common payment nature for MK-3222 is "Unspecified" ($1.2M, 99.2% of total).
MK-3222 is associated with 2 research studies, including "A 64-Week, Phase 3, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety,Tolerability of Subcutaneous SCH 900222,MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis Protocol No. MK-3222-010" ($620,782).